non-small cell lung cancer

Six diseases reap benefits of biomarkers, genetic tests
Six diseases reap benefits of biomarkers, genetic testsBiomarker testing for harmful genetic mutations provides the opportunity to identify at-risk individuals who might benefit from risk modification strategies and/or enhanced disease screening.
Three drug trends impacting specialty pharmacyAMCP session, “Specialty Pharmaceutical in Development,” highlighted critical trends that healthcare executives should be watching
FDA expands Opdivo use for metastatic melanomaFDA has approved Bristol-Myers Squibb’s Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the treatment of patients with metastatic melanoma.
Keytruda approved as first-line melanoma treatmentSales of Merck’s Keytruda (pembrolizumab) are expected to increase, after FDA approved the drug for first-line treatment of melanoma.
FDA approves Portrazza for specific type of lung cancerIn its latest round of cancer drug approvals, the FDA last week approved Portrazza (necitumumab) in combination with two forms of chemotherapy to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC).
FDA expands use for lung cancer drugSoon after the FDA granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC), it approved Opdivo (nivolumab) for an expanded use – to treat patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy.
First 2-drug combo for advanced melanoma, plus 5 more FDA actionsFirst 2-drug therapy approved for advanced melanoma and four other recent approvals by FDA relating to new drugs and treatments.
Oncology drugs in the pipelineSeveral new drugs hold promise, but cost is a top concern.
FDA approves treatments for advanced melanoma, lung cancerFDA has approved cancer therapies, one targeting metastatic melanoma and the other for metastatic non-small cell lung cancer (NSCLC).
Keytruda for lung cancer gets accelerated approvalFDA granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC) whose disease has progressed after other treatments and with tumors that express a protein called PD-L1.